Laurie Smaldone - Apr 3, 2024 Form 4 Insider Report for Kinnate Biopharma Inc. (KNTE)

Role: Director
Signature: /s/ James P. Reilly, Attorney-in-Fact
Stock symbol: KNTE
Transactions as of: Apr 3, 2024
Transactions value $: $0
Form type: 4
Date filed: 4/5/2024, 04:55 PM
Previous filing: Mar 4, 2024
Next filing: May 10, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Shares	Change %	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNTE	Stock Option (right to buy)	Disposed to Issuer	-60.8K	-100%	Apr 3, 2024	Common Stock	60.8K	$5.63	Direct	F1
transaction	KNTE	Stock Option (right to buy)	Disposed to Issuer	-20.3K	-100%	Apr 3, 2024	Common Stock	20.3K	$24.46	Direct	F1
transaction	KNTE	Stock Option (right to buy)	Disposed to Issuer	-20.3K	-100%	Apr 3, 2024	Common Stock	20.3K	$8.38	Direct	F1
transaction	KNTE	Stock Option (right to buy)	Disposed to Issuer	-25K	-100%	Apr 3, 2024	Common Stock	25K	$3.48	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Laurie Smaldone is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.

Content

This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.